found Documents: 833

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Nov 2016

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

1 item

Press Release London: Monday, November 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokineti

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 1 Nov 2016

Director's Share Dealing

1 item

London: Tuesday, November 1, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the �

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 31 Oct 2016

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

1 item

Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 12 Oct 2016

Director's Share Dealing

1 item

London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 9 Aug 2016

Director's Share Dealing

1 item

London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Change of Non-executive Directors

1 item

London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha

View Announcement (PDF)

Announcements & Press Releases, Group | 2 Aug 2016

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

1 item

Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment. Innovation Platform – Seven drug candidates in 25

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 1 Aug 2016

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

1 item

First global pivotal Phase III in c-Met-driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near future London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 glo

View Announcement (PDF)

Announcements & Press Releases, Group | 5 Jul 2016

Chi-Med to Announce 2016 Half-Year Financial Results

1 item

London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2016

Blocklisting Six Monthly Return

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jun 2016

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

2 items

Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-am

Savolitinib Clinical Trials Summary (PDF)View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 15 Jun 2016

Block Admission

1 item

London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 May 2016

Total Voting Rights

1 item

London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 May 2016

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

1 item

London: Friday, May 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced

View Announcement (PDF)

Group, Press Releases | 4 May 2016

Chi-Med to Participate in Two Healthcare Investor Conferences in May

London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May. Conference Details: E

Announcements & Press Releases, Regulatory Notice | 29 Apr 2016

Total Voting Rights

1 item

London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 27 Apr 2016

Results of Annual General Meeting

1 item

London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas

View Announcement (PDF)

Announcements & Press Releases, Group | 13 Apr 2016

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

1 item

London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Apr 2016

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

1 item

London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Mar 2016

Total Voting Rights

1 item

London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Mar 2016

Director's Shareholding

1 item

London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 23 Mar 2016

Holding(s) in Company

1 item

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is

View Announcement (PDF)

Announcements & Press Releases, Group, Press Releases | 22 Mar 2016

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

2 items

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

View Announcement (PDF)View Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 21 Mar 2016

Director's Shareholding

1 item

London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Mar 2016

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients

1 item

London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s

View Announcement (PDF)

Announcements & Press Releases, Group | 18 Mar 2016

Final Prospectus

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 17 Mar 2016

Pricing of U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group, Press Coverage | 17 Mar 2016

Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs

1 item

Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app

View Announcement (PDF)

Announcements & Press Releases, Group | 15 Mar 2016

2015 Annual Report and Notice of Annual General Meeting

1 item

London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The

View Announcement (PDF)

Announcements & Press Releases, Group | 7 Mar 2016

Repeat of Announcement of Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 4 Mar 2016

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

1 item

Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f

View Announcement (PDF)

Announcements & Press Releases, Group | 4 Mar 2016

Fifth Public Filing of Registration Statement on Form F-1 and Launch of Potential U.S. Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 2 Mar 2016

Chi-Med initiates sulfatinib Phase II clinical trial in thyroid cancer

1 item

London: Wednesday, 2 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated an open-label Phase II clinical trial to evaluate t

View Announcement (PDF)

Announcements & Press Releases, Group | 1 Mar 2016

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

View Full Announcement (PDF)

Announcements & Press Releases, Group | 1 Mar 2016

Final Results for the year ended 31 December 2015

5 items

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

View Full Announcement (PDF)View Announcement Summary (PDF)View Chairman's Statement (PDF)View Operations Review (PDF)View Financial Statements (PDF)

Announcements & Press Releases, Group | 11 Feb 2016

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jan 2016

Notice of Announcement of 2015 Final Results

London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016. An analyst presentation will be held at 9:00 am on the

Announcements & Press Releases, Oncology / Immunology, Press Releases | 15 Jan 2016

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia

1 item

London: Friday, 15 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with haema

View PDF

Announcements & Press Releases, Regulatory Notice | 29 Dec 2015

Blocklisting Six Monthly Return

1 item

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutc

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Dec 2015

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

1 item

London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist

View Announcement (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 9 Dec 2015

US$105 million Shanghai land compensation agreement

1 item

Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Dec 2015

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer

1 item

London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu

View Announcement (PDF)

Announcements & Press Releases, Group | 13 Nov 2015

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

1 item

The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM

View Full Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 10 Nov 2015

Results of Extraordinary General Meeting

1 item

London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 9 Nov 2015

Director's Share Dealing

1 item

London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Nov 2015

Chi-Med initiates sulfatinib U.S. clinical trials

1 item

London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 30 Oct 2015

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

1 item

Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Oct 2015

Total Voting Rights

1 item

London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Oct 2015

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers

1 item

London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Oct 2015

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

1 item

London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt

View Announcement (PDF)

1 2 3 4 5 6 7 8 9 10 11

13 14 15 16 17